List view / Grid view
GSK announced that the European Commission has granted marketing authorisation…
2 September 2013 | By GlaxoSmithKline
GSK announced that the European Commission has granted marketing authorisation for Tafinlar™ (dabrafenib)...
“Today’s announcement is important for women with this specific type…
14 August 2013 | By GlaxoSmithKline
“Today’s announcement is important for women with this specific type of metastatic breast cancer..."
BRAF-inhibitor Tafinlar® (dabrafenib) capsules and the first MEK-inhibitor Mekinist™ (trametinib)…
29 May 2013 | By GlaxoSmithKline
BRAF-inhibitor Tafinlar® (dabrafenib) capsules and the first MEK-inhibitor Mekinist™ (trametinib) tablets approved by FDA...
GlaxoSmithKline plc announced that the U.S. FDA has approved PROMACTA…
19 November 2012 | By GlaxoSmithKline
GlaxoSmithKline plc announced that the U.S. FDA has approved PROMACTA for the treatment of thrombocytopenia...
The pivotal Phase III study COMPARZ has met its primary…
1 October 2012 | By GlaxoSmithKline
The pivotal Phase III study COMPARZ has met its primary endpoint...
The European Commission has granted pazopanib marketing authorisation...
7 August 2012 | By GlaxoSmithKline
The European Commission has granted pazopanib marketing authorisation...
GlaxoSmithKline plc announced that the U.S. FDA has approved Votrient®…
26 April 2012 | By GlaxoSmithKline
GlaxoSmithKline plc announced that the U.S. FDA has approved Votrient® (pazopanib)...
GlaxoSmithKline announced the start of two global Phase III studies…
24 January 2011 | By GlaxoSmithKline
GlaxoSmithKline announced the start of two global Phase III studies in advanced or metastatic melanoma patients with a BRAF V600 mutation...
